

Martin Perez-Santos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/35543/publications.pdf>

Version: 2024-02-01

31
papers

348
citations

840776

11
h-index

839539

18
g-index

31
all docs

31
docs citations

31
times ranked

547
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug repurposing of adapalene for melanoma treatment. <i>Pharmaceutical Patent Analyst</i> , 2022, 11, 9-14.	1.1	2
2	OX40 agonists for cancer treatment: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 81-90.	5.0	8
3	Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. <i>Pharmaceutical Patent Analyst</i> , 2021, 10, 67-72.	1.1	0
4	Neurophysiological Mechanisms Related to Pain Management in Bone Tumors. <i>Current Neuropharmacology</i> , 2021, 19, 308-319.	2.9	3
5	Bispecific anti-OX40/5T4 antibodies for cancer treatment. <i>Pharmaceutical Patent Analyst</i> , 2021, 10, 59-66.	1.1	1
6	Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. <i>Pharmaceutical Patent Analyst</i> , 2021, 10, 245-250.	1.1	0
7	Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 83-86.	5.0	4
8	Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 723-727.	5.0	2
9	Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 487-494.	5.0	9
10	Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 307-311.	5.0	6
11	Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652. <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 159-162.	5.0	3
12	Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors. <i>Pharmaceutical Patent Analyst</i> , 2020, 9, 149-154.	1.1	4
13	LAG-3 antagonists by cancer treatment: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 643-651.	5.0	22
14	Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 921-924.	5.0	12
15	Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 481-485.	5.0	3
16	Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 587-593.	5.0	23
17	Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. <i>Expert Opinion on Therapeutic Patents</i> , 2019, 29, 311-314.	5.0	6
18	Nanostructured Systems in Advanced Drug Targeting for the Cancer Treatment: Recent Patents. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 85-94.	1.6	5

#	ARTICLE	IF	CITATIONS
19	Bursera copallifera Extracts Have Cytotoxic and Migration-Inhibitory Effects in Breast Cancer Cell Lines. Integrative Cancer Therapies, 2018, 17, 654-664.	2.0	11
20	Emerging Drugs for the Treatment of Breast Cancer Brain Metastasis: A Review of Patent Literature. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 348-359.	1.6	2
21	Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools. Genes, 2017, 8, 217.	2.4	24
22	Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent Patents. Recent Patents on Anti-Cancer Drug Discovery, 2017, 12, 81-93.	1.6	2
23	Innovation Status of Gene Therapy for Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 16, 4133-4136.	1.2	5
24	Cervical Cancer Trends in Mexico: Incidence, Mortality and Research Output. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8689-8692.	1.2	18
25	Female Breast Cancer Incidence and Mortality in Mexico, 2000-2010. Asian Pacific Journal of Cancer Prevention, 2014, 15, 1477-1479.	1.2	15
26	Mexican Breast Cancer Research Output, 2003-2012. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5921-5923.	1.2	14
27	Effect of Botulinum Toxin A on Proliferation and Apoptosis in the T47D Breast Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2013, 14, 891-894.	1.2	41
28	miR-153 Silencing Induces Apoptosis in the MDA-MB-231 Breast Cancer Cell Line. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2983-2986.	1.2	24
29	miR-485 Acts as a Tumor Suppressor by Inhibiting Cell Growth and Migration in Breast Carcinoma T47D Cells. Asian Pacific Journal of Cancer Prevention, 2013, 14, 3757-3760.	1.2	32
30	An ecto-protein tyrosine phosphatase of Entamoeba histolytica induces cellular detachment by disruption of actin filaments in HeLa cells. International Journal for Parasitology, 2003, 33, 663-670.	3.1	29
31	In vitro indomethacin administration upregulates interleukin-12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with Leishmania mexicana. Parasite Immunology, 2001, 23, 599-606.	1.5	18